Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

Therapeutic vaccination of chronic hepatitis C nonresponder patients with the peptide vaccine IC41.

Klade CS, Wedemeyer H, Berg T, Hinrichsen H, Cholewinska G, Zeuzem S, Blum H, Buschle M, Jelovcan S, Buerger V, Tauber E, Frisch J, Manns MP.

Gastroenterology. 2008 May;134(5):1385-95. doi: 10.1053/j.gastro.2008.02.058. Epub 2008 Mar 4.

PMID:
18471515
2.

Immunogenicity and safety of a novel therapeutic hepatitis C virus (HCV) peptide vaccine: a randomized, placebo controlled trial for dose optimization in 128 healthy subjects.

Firbas C, Jilma B, Tauber E, Buerger V, Jelovcan S, Lingnau K, Buschle M, Frisch J, Klade CS.

Vaccine. 2006 May 15;24(20):4343-53. Epub 2006 Mar 20.

PMID:
16581161
3.

Therapeutic vaccine IC41 as late add-on to standard treatment in patients with chronic hepatitis C.

Wedemeyer H, Schuller E, Schlaphoff V, Stauber RE, Wiegand J, Schiefke I, Firbas C, Jilma B, Thursz M, Zeuzem S, Hofmann WP, Hinrichsen H, Tauber E, Manns MP, Klade CS.

Vaccine. 2009 Aug 13;27(37):5142-51. doi: 10.1016/j.vaccine.2009.06.027. Epub 2009 Jun 24.

PMID:
19559112
4.

The cellular immune responses induced in the follow-up of interferon-alpha treated patients with chronic hepatitis C may determine the therapy outcome.

Löhr HF, Gerken G, Roth M, Weyer S, Schlaak JF, Meyer zum Büschenfelde KH.

J Hepatol. 1998 Oct;29(4):524-32.

PMID:
9824260
5.

Functional and phenotypic characterization of peptide-vaccine-induced HCV-specific CD8+ T cells in healthy individuals and chronic hepatitis C patients.

Schlaphoff V, Klade CS, Jilma B, Jelovcan SB, Cornberg M, Tauber E, Manns MP, Wedemeyer H; IC41 Study Group.

Vaccine. 2007 Sep 17;25(37-38):6793-806. Epub 2007 Jun 29.

PMID:
17686555
6.

A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.

Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoël M, Trépo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspé G.

Gastroenterology. 2011 Sep;141(3):890-899.e1-4. doi: 10.1053/j.gastro.2011.06.009. Epub 2011 Jun 13.

PMID:
21699798
7.

Recurrence of hepatitis C virus after loss of virus-specific CD4(+) T-cell response in acute hepatitis C.

Gerlach JT, Diepolder HM, Jung MC, Gruener NH, Schraut WW, Zachoval R, Hoffmann R, Schirren CA, Santantonio T, Pape GR.

Gastroenterology. 1999 Oct;117(4):933-41.

PMID:
10500077
8.

Restoration of HCV-specific T cell functions by PD-1/PD-L1 blockade in HCV infection: effect of viremia levels and antiviral treatment.

Urbani S, Amadei B, Tola D, Pedrazzi G, Sacchelli L, Cavallo MC, Orlandini A, Missale G, Ferrari C.

J Hepatol. 2008 Apr;48(4):548-58. doi: 10.1016/j.jhep.2007.12.014. Epub 2008 Jan 28. Erratum in: J Hepatol. 2008 Sep;49(3):483.

PMID:
18280607
9.

Virus-specific T-cell responses associated with hepatitis C virus (HCV) persistence in the liver after apparent recovery from HCV infection.

Quiroga JA, Llorente S, Castillo I, Rodríguez-Iñigo E, López-Alcorocho JM, Pardo M, Carreño V.

J Med Virol. 2006 Sep;78(9):1190-7.

PMID:
16847959
10.

Genetic variability of hepatitis C virus non-structural protein 3 and virus-specific CD8+ response in patients with chronic hepatitis C.

López-Labrador FX, He XS, Berenguer M, Cheung RC, González-Candelas F, Wright TL, Greenberg HB.

J Med Virol. 2004 Apr;72(4):575-85.

PMID:
14981760
11.

Evidence of hepatitis C virus-specific interferon gamma-positive T cells in health care workers in an infectious disease department.

Perrella A, Grattacaso S, d'Antonio A, Atripaldi L, Sbreglia C, Gnarini M, Conti P, Vecchiet J, Perrella O.

Am J Infect Control. 2009 Jun;37(5):426-9. doi: 10.1016/j.ajic.2008.08.003. Epub 2009 Jan 19.

PMID:
19155099
12.

Genetic immunization and comprehensive screening approaches in HLA-A2 transgenic mice lead to the identification of three novel epitopes in hepatitis C virus NS3 antigen.

Martin P, Parroche P, Chatel L, Barretto C, Beck A, Trépo C, Bain C, Lone YC, Inchauspé G, Fournillier A.

J Med Virol. 2004 Nov;74(3):397-405.

PMID:
15368525
13.

HLA-A2-restricted cytotoxic T lymphocyte activity during interferon beta therapy in patients with chronic hepatitis C.

Ohira H, Iwasaki M, Takiguchi J, Rai T, Shishido S, Abe K, Takeda J, Tojo J, Sato Y, Kasukawa R.

Fukushima J Med Sci. 2002 Dec;48(2):75-83.

14.

HCV-NS3 Th1 minigene vaccine based on invariant chain CLIP genetic substitution enhances CD4(+) Th1 cell responses in vivo.

Gao M, Wang HP, Wang YN, Zhou Y, Wang QL.

Vaccine. 2006 Jun 29;24(26):5491-7. Epub 2006 Apr 24.

PMID:
16725235
15.

Immunization with a DNA vaccine candidate in chronic hepatitis C patients is safe, well tolerated and does not impair immune response induction after anti-hepatitis B vaccination.

Castellanos M, Cinza Z, Dorta Z, Veliz G, Vega H, Lorenzo I, Ojeda S, Dueñas-Carrera S, Alvarez-Lajonchere L, Martínez G, Ferrer E, Limonta M, Linares M, Ruiz O, Acevedo B, Torres D, Márquez G, Herrera L, Arús E.

J Gene Med. 2010 Jan;12(1):107-16. doi: 10.1002/jgm.1407.

PMID:
19866482
16.

Lack of optimal T-cell reactivity against the hepatitis C virus is associated with the development of fibrosis/cirrhosis during chronic hepatitis.

Sreenarasimhaiah J, Jaramillo A, Crippin J, Lisker-Melman M, Chapman WC, Mohanakumar T.

Hum Immunol. 2003 Feb;64(2):224-30.

PMID:
12559624
17.

Regulatory T cells suppress in vitro proliferation of virus-specific CD8+ T cells during persistent hepatitis C virus infection.

Rushbrook SM, Ward SM, Unitt E, Vowler SL, Lucas M, Klenerman P, Alexander GJ.

J Virol. 2005 Jun;79(12):7852-9.

18.

Phase I clinical study of a personalized peptide vaccination for patients infected with hepatitis C virus (HCV) 1b who failed to respond to interferon-based therapy.

Yutani S, Yamada A, Yoshida K, Takao Y, Tamura M, Komatsu N, Ide T, Tanaka M, Sata M, Itoh K.

Vaccine. 2007 Oct 16;25(42):7429-35. Epub 2007 Aug 24.

PMID:
17845828
19.

Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection.

Spangenberg HC, Viazov S, Kersting N, Neumann-Haefelin C, McKinney D, Roggendorf M, von Weizsäcker F, Blum HE, Thimme R.

Hepatology. 2005 Oct;42(4):828-37.

PMID:
16175596
20.

Liver-derived hepatitis C virus (HCV)-specific CD4(+) T cells recognize multiple HCV epitopes and produce interferon gamma.

Schirren CA, Jung MC, Gerlach JT, Worzfeld T, Baretton G, Mamin M, Hubert Gruener N, Houghton M, Pape GR.

Hepatology. 2000 Sep;32(3):597-603.

PMID:
10960455

Supplemental Content

Support Center